



BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2012

PART - I (Rs. in Lakhs)

SR. NO.	PARTICULARS	STANDALONE					
		QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31.12.2012 (UNAUDITED)	30.09.2012 (UNAUDITED)	31.12.2011 (UNAUDITED)	31.12.2012 (UNAUDITED)	31.12.2011 (UNAUDITED)	31.03.2012 (AUDITED)
1	Income from operations						
	(a) Net Sales (Net of Excise Duty)	8131.68	10292.27	6296.05	24798.11	19371.01	26442.53
	(b) Other Operating Income	52.80	194.34	77.16	306.80	157.04	224.96
	Total Income from operations (Net)	8184.48	10486.61	6373.22	25104.91	19528.05	26667.49
2	Expenses						
	a) Consumption of Raw Materials	4567.95	5157.38	3,623.71	13,242.81	10,426.36	14799.48
	b) Purchase of Traded Goods	0.00	247.61	674.95	307.77	783.67	1001.29
	c) (Increase)/Decrease in Stock in Trade	-440.05	232.40	-101.21	-417.08	97.11	-53.60
	d) Employee Benefit Expenses	282.48	235.06	148.12	714.17	426.23	603.15
	e) Depreciation / Amortisation	105.86	110.47	0.75	323.07	299.09	364.61
	f) Other Expenditure	1305.97	939.01	926.05	2927.77	2302.11	3198.95
	Total Expenses	5822.21	6921.92	5274.36	17098.51	14334.57	19913.88
3	Profit from Operations before other Income & Finance Cost & Exceptional items (1-2)	2362.28	3564.69	1098.85	8006.40	5193.48	6753.61
4	Other Income	278.09	98.73	577.55	771.46	1188.60	1620.05
5	Profit from Ordinary Activities Before Finance Cost (3+4)	2640.37	3563.42	1676.41	8777.86	6382.08	8373.66
6	Finance Cost	220.46	133.30	69.33	434.34	218.62	402.41
7	Profit from Ordinary Activities after Finance Cost but before Exceptional Items (5-6)	2419.91	3530.12	1607.08	8343.52	6163.45	7971.25
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax	2419.91	3530.12	1607.08	8343.52	6163.45	7971.25
10	Tax Expense (including Deferred Tax)	1481.02	1060.72	721.70	3245.74	1647.24	2688.35
11	Net Profit after Tax for the Period	938.89	2469.40	885.38	5097.78	4516.22	5282.90
12	Paid-up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
13	Reserves including Revaluation Reserve (as Per Balance Sheet)	-	-	-	-	-	-
14	Basic and Diluted EPS (Not Annualised)	0.91	2.39	0.86	4.94	4.38	5.12

PART - II

A	Particulars of Shareholding	Quarter ended 31 DECEMBER 2012					
1	Aggregate of Non-promoter Shareholding						
	- No. of Shares (Face Value Rs. 1/- Each)	36187842	36188842	36187842	36187842	36187842	36187842
	- Percentage of Shareholding (%)	35.08	35.08	35.08	35.08	35.08	35.08
2	Promoter and Promoter Group Shareholding						
	A) Pledge/ Encumbered						
	- No. of Shares (Face Value Re. 1/- Each)	-	-	-	-	-	-
	- Percentage of Shares (As % of The Total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (As % of the Total Share Capital of the Company)	-	-	-	-	-	-
	B) Non - Encumbered						
	- No. of Shares (Face Value Re. 1/- Each)	66958830	66957830	66958830	66958830	66958830	66958830
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the Total Share Capital of the Company)	64.92	64.92	64.92	64.92	64.92	64.92

B	INVESTOR COMPLAINTS	Quarter ended 31 DECEMBER 2012					
	Pending at the beginning of the quarter						
	Received during the quarter				5		
	Disposed off during the quarter				5		
	REMAINING UNSOLVED AT THE END OF THE QUARTER						

Notes:-

- The company operates primarily in the pharmaceutical business and hence has only one reportable segment.
- The statutory auditors have carried out "limited review" of the aforesaid results.
- The above results were reviewed by the audit committee & were there after approved by the board at its meeting held on 13 Feb, 2013.
- In view of the extant volatility in exchange rates and considering longer duration of exports receivables, unrealised exchange gains aggregating to Rs. 930 lakhs which would have been reported on such exports receivables at the closing rate is not accounted for in the above interim financial statements. The same will be recognised in the books on actual settlement or at the year end which ever is earlier. The statutory auditors have brought this fact to the notice in their limited review report.
- Tax expense for the nine months and current quarter includes short provision of Rs. 700.96 lacs pertaining to earlier years.
- The board has recommended an interim dividend of 30% i.e. 0.30 per equity share for the year 2012-2013.

Place : Mumbai
Date : 13-02-2013



FOR BLISS GVS PHARMA LIMITED
SD/-
S. N. KAMATH
MANAGING DIRECTOR

Size : 28 cm (h) X 17 cm (w)

Head Office : Mumbai

- Tel : (022) 2200 0607 / 7318 / 6360
(022) 6631 5835 / 36
- Fax : (022) 2200 3476
- E-mail : info@bkkhareco.com
- 706 / 708, Sharda Chambers,
New Marine Lines, Mumbai 400 020

B. K. KHARE & Co.
CHARTERED ACCOUNTANTS

The Board of Directors
Bliss GVS Pharma Limited
Mumbai.

Dear Sirs,

Limited Review Report

We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **Bliss GVS Pharma Limited** for the period ended 31st December, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Other Committee. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with stock exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

Branch Office : Pune

- Tel : (020) 64019743 / 25666932 / 32926341
- E-mail : pune@bkkhareco.com
- Hotel Swaroop, 4th Floor, Lane No.10,
Prabhat Road, Erandwane, Pune - 411 004.

**Branch Office : Bengaluru**

- Tel : (080) 4110 5357 •
- E-mail : bkkhareb@vsnl.net •
- 101, Money Chambers, 1st Floor •
- # 6 K. H. Road, Shanthinagar, Bengaluru - 560027